Abstract: A filler treatment process enhances the fixation of anionic latex on filler in a short time. Anionic polymer dispersions (latex) are added to papermaking filler slurries at ambient temperature and then mixed with water of temperature higher than the glass transition temperature (Tg) of the latex used. The anionic latexes applied by this process are totally and irreversibly fixed or bound onto the filler particles and the treated filler particle agglomerate to form an aggregated filler slurry which is stable over time. The latex-treated filler slurry can be added to papermaking furnishes at any point prior to the headbox of the paper machine or stored for later use. The latex-treated filler slurry improves filler retention, only slightly reduces sheet strength and improves sizing performance.

Abstract: A continuous filler treatment process has been developed to enhance the fixation of anionic latex on filler in a short time. In this process anionic polymer dispersions (latex) are added to common papermaking filler slurries at ambient temperature and then mixed with water of temperature higher than the glass transition temperature (Tg) of the latex used. To efficiently fix the latex the temperature of the filler/latex mixture must be 30-60° C. higher than the Tg of the latex used. The chemical composition of the resin and the type of surfactant used during the emulsion polymerisation process of the polymer latex dispersions are important factors for efficiently fixing the latex onto the filler by adding hot water and improving the properties of paper made with the treated filler. The enhanced fixation of anionic latex onto filler using hot water is done in mixing vessels that can control shear and mixing time.

Abstract: A continuous fiIter treatment process in which anionic polymer dispersions (latex) are added to common papermaking filler slurries ai ambient temperature and then mixed with water of temperature higher than the glass transition temperature (Tg) of the latex used. To efficiently fix the latex the temperature of the filler/latex mixture must be 30-60° C. higher than ihe Tg of the latex used. The chemical composition of the resin and the type of surfactant used during the emulsion polymerization process of the polymer latex dispersions are important factors for efficiently fixing the latex onto the filler by adding hot water and improving the properties of paper made with the treated filler. Enhanced fixation of anionic latex onto filler using hot water is done in mixing vessels that can control shear and mixing time. The anionic latexes are totally and irreversibly fixed or bound onto the filler particles and the aggregated filler slurry is stable over time.

Abstract: A continuous filler treatment process has been developed to enhance the fixation of anionic latex on filler in a short time. In this process anionic polymer dispersions (latex) are added to common papermaking filler slurries at ambient temperature and then mixed with water of temperature higher than the glass transition temperature (Tg) of the latex used. To efficiently fix the latex the temperature of the filler/latex mixture must be 30-60° C. higher than the Tg of the latex used. The chemical composition of the resin and the type of surfactant used during the emulsion polymerisation process of the polymer latex dispersions are important factors for efficiently fixing the latex onto the filler by adding hot water and improving the properties of paper made with the treated filler. The enhanced fixation of anionic latex onto filler using hot water is done in mixing vessels that can control shear and mixing time.

Abstract: The present invention is directed to novel 3-piperidin-4-yl-indole derivatives of formula (I) and forms thereof, wherein X, R1, R2, R3, R4 and R5 are as herein defined, pharmaceutical compositions thereof and use as ORL-1 receptor modulators for treating, preventing or ameliorating ORL-1 receptor mediated disorders and conditions.

Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.

Abstract: The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.

Abstract: The present invention is directed to novel thiazolopyrimidine compounds of Formula (I) or a form or composition thereof and the thereof as inhibitors of ATP-protein kinase interactions.

Abstract: The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

Abstract: The present invention is directed to novel 3-spirocyclic indolyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the ORL-1 receptor.

Abstract: The present invention relates to substituted isoindole-1,3-dione compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

Abstract: An electronic assembly includes a bare IC die or a leadless electronic component having at least one electrically conductive contact formed on a surface of the component and a leadframe or a substrate having at least one electrically conductive trace. The conductive contact of the component is electrically and mechanically coupled to the conductive trace with a solder joint. The solder joint includes a plurality of solid electrically conductive metal particles having a substantially spherical shape and a diameter ranging from about one mil to about ten mils.

Abstract: The present invention relates to piperazine substituted cyclohexane- 1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

Abstract: The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.

Abstract: The present invention provides pyrimidinyl substituted fused-pyrrolyl compounds of Formula (I) and pharmaceutical compositions comprising the compounds and methods of synthesis and use thereof. The compounds are kinase inhibitors useful in treating or ameliorating a kinase mediated, angiogenesis-mediated or hyperproliferative disorder. The invention thus also provides a therapeutic or prophylactic method of use for the compounds and/or pharmaceutical compositions to treat such disorders.

Abstract: The present invention relates to new compounds of Formula (I): and pharmaceutically acceptable forms thereof, use of the compounds as ?1a and/or ?1d adrenoreceptor modulators, including use of a pharmaceutical composition, medicine or medicament comprising said compounds, a process to prepare said compounds and a method for treating an ?1a and/or ?1d adrenoreceptor mediated disorder.

Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.

Abstract: The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable form thereof, as dual selective ?1a/?1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.

Abstract: The present invention is directed to novel thiazolopyridines, pharmaceutical compositions thereof, and the use thereof as inhibitors of ATP-protein kinase interactions.

Abstract: The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.